FINWIRES · TerminalLIVE
FINWIRES

Bank of Canada Is in No Hurry to React to Higher Oil Prices, Says Desjardins

By

-- The Bank of Canada's Governing Council left rates unchanged at 2.25% on Wednesday and signaled that elevated oil prices won't do much to boost gross domestic product or underlying inflationary pressures, said Desjardins.

For its projections, the BoC assumed that Brent oil prices will fall to around US$75/barrel by mid-2027, roughly in line with the bank's forecasts.

That said, policymakers expect investment and employment to be less responsive to higher crude prices than in the past, leaving real gross domestic product up just 1.2% in 2026, while previously it saw at 1.1%. So while the composition of growth will look different -- many households and businesses will be squeezed by higher energy costs even as some firms and governments benefit -- the economy is still expected to absorb slack only slowly this year, stated Desjardins.

The good news is that officials share the bank's view that spillovers to core inflation will be limited. The BoC expects core inflation to end 2026 at 2.0%, which is actually a touch lower than the 2.1% penciled in back in January's Monetary Policy Report (MPR).

The commentary accompanying the rate decision also highlighted the favorable starting point for underlying inflation, with the BoC's preferred core measures just slightly above 2% in March and the proportion of components rising above 3% also having declined in recent months. So while officials acknowledged the cost pressures associated with high oil prices, they implied that their operational target, underlying inflation, wouldn't be impacted, added the bank.

Wednesday's MPR also included projections for an alternative scenario in which oil prices remain around US$100 per barrel. Even in that scenario, the economy is expected to struggle over the next few years, as many households and businesses would face higher costs and the benefits of elevated crude prices would translate into increased activity in oil-producing regions with a lag.

That said, the forecasts include a further rise in headline inflation, which is substantially more persistent and broad-based than in the base case projections. Governor Tiff Macklem appears to suggest that such a situation could warrant consecutive increases in the policy rate, according to Desjardins.

Overall, the BoC appears comfortable leaving rates unchanged for the rest of the year, unless oil prices remain high, added the bank. Assuming oil prices decline to levels consistent with their assumptions, the central bank's communications suggest that any changes in the target rate will be small.

Desjardins takes that to mean that once the economy recovers to full health, central bankers will raise the policy rate gradually to 2.75%, the mid-point of their estimated neutral rate range. The bank's expectation is that those rate increases aren't in the cards until 2027.

Related Articles

Research

Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.

$INCY
Australia

GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease

GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%

$GSK
International

ISM US Manufacturing Index Indicates Steady Expansion in April

The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.